TY - JOUR
T1 - An update on usage of high-risk donors in liver transplantation
AU - Muhammad, Haris
AU - Zaffar, Duha
AU - Tehreem, Aniqa
AU - Ting, Peng Sheng
AU - Simsek, Cem
AU - Turan, Ilker
AU - Alqahtani, Saleh
AU - Saberi, Behnam
AU - Gurakar, Ahmet
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - The ideal management for end stage liver disease, acute liver failure, and hepatocellular carcinoma (HCC), within specific criteria, is liver transplantation (LT). Over the years, there has been a steady increase in the candidates listed for LT, without a corresponding increase in the donor pool. Therefore, due to organ shortage, it has been substantially difficult to reduce waitlist mortality among patients awaiting LT. Thus, marginal donors such as elderly donors, steatotic donors, split liver, and donors after cardiac death (DCD), which were once not commonly used, are now considered. Furthermore, it is encouraging to see the passing of Acts, such as the HIV Organ Policy Equity (HOPE) Act, enabling further research and development in utilizing HIV grafts. Subsequently, the newer antivirals have aided in successful post-transplant period, especially for hepatitis C positive grafts. However, currently, there is no standardization, and protocols are center specific in the usage of marginal donors. Therefore, studies with longer follow ups are required to standardize its use.
AB - The ideal management for end stage liver disease, acute liver failure, and hepatocellular carcinoma (HCC), within specific criteria, is liver transplantation (LT). Over the years, there has been a steady increase in the candidates listed for LT, without a corresponding increase in the donor pool. Therefore, due to organ shortage, it has been substantially difficult to reduce waitlist mortality among patients awaiting LT. Thus, marginal donors such as elderly donors, steatotic donors, split liver, and donors after cardiac death (DCD), which were once not commonly used, are now considered. Furthermore, it is encouraging to see the passing of Acts, such as the HIV Organ Policy Equity (HOPE) Act, enabling further research and development in utilizing HIV grafts. Subsequently, the newer antivirals have aided in successful post-transplant period, especially for hepatitis C positive grafts. However, currently, there is no standardization, and protocols are center specific in the usage of marginal donors. Therefore, studies with longer follow ups are required to standardize its use.
KW - Donors after cardiac death
KW - HIV Organ Policy Equity (HOPE) Act
KW - Liver transplantation
KW - Split liver
KW - Steatotic donors
UR - http://www.scopus.com/inward/record.url?scp=85122004023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122004023&partnerID=8YFLogxK
U2 - 10.3390/jcm11010215
DO - 10.3390/jcm11010215
M3 - Review article
C2 - 35011956
AN - SCOPUS:85122004023
SN - 2077-0383
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 1
M1 - 215
ER -